Drug intelligence / Profile preview

UBP-3004

Development stage: Preclinical
Lead developer: UWELL Biopharma
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

UBP-3004 (also known as UWC19) is a preclinical-stage chimeric antigen receptor (CAR) T-cell therapy being developed by UWELL Biopharma. The therapy involves engineering T cells to express a CAR directed against CD19, a cell surface protein widely expressed on B-cell malignancies. By targeting CD19, UBP-3004 is designed to recognize and selectively eliminate malignant B cells. It is currently under development for the treatment of B-cell acute lymphoblastic leukemia (B-ALL).

Other names: UWC19UWC-19UWC 19

Targets

CD19 (B lymphocyte antigen CD19)

Beyond the preview

Go deeper on UBP-3004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UBP-3004.

Explore the full profile